Current Research

The Pulmonary Research team at the Cedars-Sinai Lung Institute comprises a group of world-class researchers whose combined interests span multiple disciplines. The unified goal is to understand the underlying mechanisms that cause various lung diseases and ultimately translate those findings to improving patient health.

The researchers at Cedars-Sinai are conducting basic, clinical and translational research in a number of pulmonary diseases such as idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, lung transplantation and lung infection, among others. Scientific programs within the Lung Institute have a bench-to-bedside approach that spans the entire research spectrum to unravel basic mechanisms of disease, develop new diagnostic modalities, and test novel therapies.

Newly built research facilities, replete with state-of-the-art equipment, keep Cedars-Sinai at the forefront of respiratory research. As an academic institution, the research laboratories are tightly integrated with the clinical facilities to promote translation of work to improving patient care. Pulmonary Research investigators are highly interactive to synergize the pulmonary research programs within the Lung Institute at Cedars-Sinai.

The Lung Institute includes several top researchers with vibrant research programs that have contributed multiple high-impact publications in the fields of lung injury, fibrosis, infection, regeneration and immunology. The basic research findings are leading to new therapies for diseases such as idiopathic pulmonary fibrosis, asthma, and COPD, in addition to identifying methods for controlling lung inflammation after infections and developing regenerative medicine tools to repair damaged lungs.

The investigators within the Lung Institute are also developing novel imaging technologies to facilitate diagnostics of several diseases such as lung cancer, pulmonary hypertension and lung transplant rejection. Furthermore, Lung Institute researchers are conducting several clinical trials for novel therapies for idiopathic pulmonary fibrosis, pulmonary hypertension and venous thromboembolic disease.